Page 357 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 25 Tolerance and Autoimmunity 293

tolerance. If the system can be set back to the state before that use immunomodulation to treat autoimmune diseases on the basis
event, the disease could be cured. At present, it is unclear how to of a better understanding of the pathogenesis.
do this; however, an autologous or even allogeneic hematopoietic
stem cell transplant may have the desired effect. In fact, this sort
of radical therapy has been tried in selected cases of severe SLE and REFERENCES
seems to have some efficacy. Another promising area is in channeling
the immune response, particularly as the steering mechanisms are 1. Nossal GJ, Pike BL: Mechanisms of clonal abortion tolerogenesis.
becoming better understood at the molecular level. A third area I. Response of immature hapten-specific B lymphocytes. J Exp Med
is to design more specific modulators of inflammation, including 148:1161, 1978.
interfering with costimulatory signals. These latter approaches have 2. Nemazee DA, Burki K: Clonal deletion of B lymphocytes in a transgenic
seemed promising in various animal models, although issues with mouse bearing anti-MHC class I antibody genes. Nature 337:562, 1989.
unexpected effects on clotting have arisen in clinical trials of CD40L 3. Gay D, Saunders T, Camper S, et al: Receptor editing: an approach by
inhibition. autoreactive B cells to escape tolerance. J Exp Med 177(4):999–1008,
Current therapy is much more crude and typically involves general 1993.
nonspecific immunosuppression either with steroids or cytotoxic 4. Tiegs SL, Russell DM, Nemazee D: Receptor editing in self-reactive bone
drugs. Although these therapies can be effective, they have numerous marrow B cells. J Exp Med 177(4):1009–1020, 1993.
undesirable side effects, not the least of which is increased suscep- 5. Sha WC, Nelson CA, Newberry RD, et al: Positive and negative
tibility to infection caused by immunosuppression. More promising selection of an antigen receptor on T cells in transgenic mice. Nature
are drugs such as monoclonal antibodies that inhibit the effects 336(6194):73–76, 1988.
of specific cytokines such as TNF-α, which have proven success- 6. Kisielow P, Bluthmann H, Staerz UD, et al: Tolerance in T-cell-receptor
ful in modifying progression of RA, inflammatory bowel disease, transgenic mice involves deletion of nonmature CD4+8+ thymocytes.
and psoriasis. Additionally, the injection of cytokines themselves Nature 333(6175):742–746, 1988.
could also be effective at treating autoimmunity. For example, IL-2 7. Anderson MS, Venanzi ES, Klein L, et al: Projection of an immu-
administration has been shown to expand regulatory T cells and nological self shadow within the thymus by the aire protein. Science
ameliorate disease in multiple autoimmune mouse models including 298(5597):1395–1401, 2002.
type I diabetes and multiple sclerosis. In human clinical trials, IL-2 8. Okamoto M, Murakami M, Shimizu A, et al: A transgenic model of
was shown to be effective in reducing chronic GVHD. It would be autoimmune hemolytic anemia. J Exp Med 175(1):71–79, 1992.
interesting to see if IL-2 and other therapies aimed at expanding 9. Shlomchik MJ, Zharhary D, Saunders T, et al: A rheumatoid factor
regulatory T cells will be an effective treatment for autoimmune transgenic mouse model of autoantibody regulation. Int Immunol
disorders. 5(10):1329–1341, 1993.
Reciprocally, therapies for autoimmune diseases in humans have 10. Goodnow CC: Transgenic mice and analysis of B-cell tolerance. Annu
in turn taught us new aspects of autoimmune disease pathogenesis. Rev Immunol 10:489–518, 1992.
A prime example of this is rituximab, which is a monoclonal anti- 11. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus func-
+
body that targets the CD20 antigen and hence depletes CD20 B tional clonal inactivation: a costimulatory signalling pathway determines
+
cells. Rituximab was originally developed to treat CD20 B cell the outcome of T cell antigen receptor occupancy. Annu Rev Immunol
29
malignancies, but during clinical trials it was unexpectedly found 7:445–480, 1989.
that cancer patients with concomitant RA showed improvement in 12. Allen RC, Armitage RJ, Conley ME, et al: CD40 ligand gene defects
their RA symptoms. This was surprising given that RA was thought responsible for X-linked hyper-IgM syndrome. Science 259(5097):990–
to be predominantly driven by T cells rather than by B cells. This 993, 1993.
finding prompted clinical trials using rituximab for the treatment 13. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al: Chromatin-IgG com-
of a number of autoimmune diseases. These include autoimmune plexes activate B cells by dual engagement of IgM and Toll-like receptors.
diseases that are clearly antibody-mediated (e.g., ITP, AIHA, TTP, Nature 416(6881):603–607, 2002.
pemphigus vulgaris) but also include those that have less well-defined 14. Inaba K, Witmer-Pack M, Inaba M, et al: The tissue distribution of the
involvement of autoantibodies (e.g., vasculitides, multiple sclerosis, B7-2 costimulator in mice: abundant expression on dendritic cells in situ
30
RA, type I diabetes). Although one might predict that rituximab and during maturation in vitro. J Exp Med 180(5):1849–1860, 1994.
attenuates autoimmunity by reducing autoantibody production by B 15. Shlomchik MJ, Aucoin AH, Pisetsky DS, et al: Structure and function
cells, this appears to not always be the case. For example, although of anti-DNA autoantibodies derived from a single autoimmune mouse.
clinically effective, rituximab only decreases levels of RF but not Proc Natl Acad Sci USA 84(24):9150–9154, 1987.
of anticitrullinated peptide antibodies in RA patients. Similarly, 16. Crotty S: T follicular helper cell differentiation, function, and roles in
antineutrophil cytoplasmic antibody (ANCA) levels are not decreased disease. Immunity 41(4):529–542, 2014.
in patients with ANCA-associated vasculitides treated with rituximab 17. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al: Lymphop-
despite clinical efficacy. In fact, it is somewhat puzzling why ritux- roliferation disorder in mice explained by defects in Fas antigen that
imab would reduce circulating antibodies at all, given that CD20 is mediates apoptosis. Nature 356(6367):314–317, 1992.
expressed on mature B cells but not on plasma cells, which provide 18. Suda T, Takahashi T, Golstein P, et al: Molecular cloning and expression
the long-lasting source of autoantibodies in chronic autoimmunity. of the Fas ligand, a novel member of the tumor necrosis factor family.
Chronic treatment of patients with rituximab depletes memory and Cell 75(6):1169–1178, 1993.
activated B cells that repopulate the pool of plasma cells that are 19. Tivol EA, Borriello F, Schweitzer AN, et al: Loss of CTLA-4 leads
turning over, which may explain why circulating antibody levels to massive lymphoproliferation and fatal multiorgan tissue destruc-
can be decreased. However, B-cell depletion by rituximab is most tion, revealing a critical negative regulatory role of CTLA-4. Immunity
likely effective in many of these autoimmune disorders because of 3(5):541–547, 1995.
the antibody-independent functions of B cells including cytokine 20. Keir ME, Butte MJ, Freeman GJ, et al: PD-1 and its ligands in tolerance
production and antigen presentation. and immunity. Annu Rev Immunol 26:677–704, 2008.
The therapeutic approaches discussed earlier, although a result of 21. Zhu J, Yamane H, Paul WE: Differentiation of effector CD4 T cell
modern biotechnology and our understanding of immunopathogen- populations (*). Annu Rev Immunol 28:445–489, 2010.
esis, still targets effector function of the immune system and does 22. Asano M, Toda M, Sakaguchi N, et al: Autoimmune disease as a conse-
not modify the root cause of disease. Therapies should ultimately quence of developmental abnormality of a T cell subpopulation. J Exp
be directed toward either prevention or else specific downregula- Med 184(2):387–396, 1996.
tion of ongoing responses. Future work will include continuing 23. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the develop-
to define how self-tolerance is imposed and how it is broken in ment and function of CD4+CD25+ regulatory T cells. Nat Immunol
disease, what the critical triggers and autoantigens are, and how to 4(4):330–336, 2003.